Company / Cash & Equivalents
Whitehawk Therapeutics, Inc. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$37.6M
FY2025
5-year range
$28.7M / $149.0M
FY2021-FY2025
Trend
+31.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 8 years, ranging from $20M in FY2018 to $149M in FY2021.
Based on SEC 10-K filings.
$38M in FY2025 with a 5-year CAGR of -2.5%.
Declined from $63M to $38M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -1.3%
- 5-Year CAGR
- -2.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -2.5%, indicating a declining trend.
- In FY2025, cash & equivalents increased 31.0% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $37.6M | +31.0% |
| FY2024 | $28.7M | -54.4% |
| FY2023 | $62.9M | +61.2% |
| FY2022 | $39.0M | -73.8% |
| FY2021 | $149.0M | +249.7% |
| FY2020 | $42.6M | +10.6% |
| FY2019 | $38.5M | +90.1% |
| FY2018 | $20.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026